Assenagon Asset Management
SYRE icon

Assenagon Asset Management’s Spyre Therapeutics SYRE Stock Holding History

Assenagon Asset Management’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-18,647
Closed -$941K – 1250
2026
Q1 		$941K Sell
18,647
-3,489
-16% -$132K ﹤0.01% 901
2025
Q4 		$725K Hold
22,136
– – ﹤0.01% 1005
2025
Q3 		$371K Hold
22,136
– – ﹤0.01% 1095
2025
Q2 		$331K Sell
22,136
-590
-3% -$8.73K ﹤0.01% 1084
2025
Q1 		$367K Buy
22,726
+74
+0.3% +$1.54K ﹤0.01% 1058
2024
Q4 		$527K Sell
22,652
-1,120,116
-98% -$32.8M ﹤0.01% 1191
2024
Q3 		$33.6M Buy
+1,142,768
New +$31.8M 0.06% 236
2024
Q2 		– Sell
-64,400
Closed -$2.44M – 1491
2024
Q1 		$2.44M Buy
+64,400
New +$1.87M 0.01% 820
2023
Q2 		– Sell
-12,738
Closed -$92.4K – 1459
2023
Q1 		$92.4K Hold
12,738
– – ﹤0.01% 1385
2022
Q4 		$143K Hold
12,738
– – ﹤0.01% 1326
2022
Q3 		$168K Sell
12,738
-12,975
-50% -$160K ﹤0.01% 1284
2022
Q2 		$325K Buy
25,713
+4,787
+23% +$168K ﹤0.01% 1311
2022
Q1 		$1.2M Buy
20,926
+4,279
+26% +$359K ﹤0.01% 1007
2021
Q4 		$1.98M Buy
16,647
+5,964
+56% +$941K 0.01% 825
2021
Q3 		$2.12M Sell
10,683
-600
-5% -$105K 0.01% 673
2021
Q2 		$1.96M Buy
11,283
+5,371
+91% +$976K 0.01% 682
2021
Q1 		$1.17M Sell
5,912
-523
-8% -$100K ﹤0.01% 895
2020
Q4 		$1.27M Buy
6,435
+1,581
+33% +$328K 0.01% 659
2020
Q3 		$860K Sell
4,854
-8,455
-64% -$1.56M ﹤0.01% 881
2020
Q2 		$3.08M Buy
+13,309
New +$2.53M 0.02% 458
2019
Q4 		– Sell
-512
Closed -$98K – 928
2019
Q3 		$98K Sell
512
-7,800
-94% -$1.52M ﹤0.01% 796
2019
Q2 		$1.42M Buy
8,312
+4,551
+121% +$787K 0.01% 626
2019
Q1 		$757K Buy
+3,761
New +$784K 0.01% 746

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Assenagon Asset Management's SYRE Position: Q2 2026 in Review

Assenagon Asset Management sold out of Spyre Therapeutics (SYRE) in Q2 2026, closing a stake of 18,647 shares — an estimated $941K sold.

Assenagon Asset Management first reported a position in SYRE in Q1 2019 and held it in 23 quarters. The position peaked at $33.6M in Q3 2024. 265 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

  • Assenagon Asset Management reported no remaining Spyre Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Assenagon Asset Management sold 18,647 Spyre Therapeutics shares in Q2 2026, an estimated $941K.
  • Assenagon Asset Management first reported a position in Spyre Therapeutics in Q1 2019 and held it in 23 quarters.
  • Assenagon Asset Management's Spyre Therapeutics position peaked at $33.6M in Q3 2024.
  • 265 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on Assenagon Asset Management's 13F filing for Q2 2026, filed 8 Jul 2026.